Synchron Raises $200 Million Series D to Propel Brain-Computer Interface Technology Forward
New York, NY – Synchron, a pioneering company in non-surgical brain-computer interface (BCI) technology, has announced the successful close of a $200 million Series D financing round. This substantial investment will accelerate the commercialization of Synchron’s first-generation Stentrode™ BCI platform and support the development of an advanced next-generation brain interface.
About the Funding Round
The Series D round was led by Double Point Ventures and saw robust participation from a variety of existing and new investors. Returning backers include ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New investors bringing fresh capital to the table feature the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and In-Q-Tel (IQT). With this latest round, Synchron’s total capital raised stands at an impressive $345 million.
Stentrode™: A First in Endovascular Brain-Computer Interfaces
Synchron’s Stentrode™ platform represents the world’s first endovascular brain-computer interface designed to decode brain activity into digital commands without the need for invasive open-brain surgery. The device is implanted via a minimally invasive catheter procedure that navigates through blood vessels to the motor cortex. It records neural signals and transmits them wirelessly, enabling users—particularly individuals with paralysis—to operate digital devices hands-free.
To date, the Stentrode has been successfully implanted in 10 patients across clinical trials conducted in the United States and Australia, marking significant progress in its pathway toward real-world applications.
Breakthrough Integration with Apple Devices
Synchron has also achieved a notable technological milestone by becoming the first BCI company to integrate with Apple’s brain-computer interface human interface device (BCI-HID). They co-developed a Bluetooth-based protocol for iOS that allows direct brain signal translation to Apple products such as the iPhone, iPad, and Apple Vision Pro. This integration enables device control without touch, voice commands, or eye-tracking, showcasing a seamless interface experience.
Expanding Operations and Future Developments
Alongside commercialization efforts, Synchron is expanding its operations with a growing Cognitive AI division based in New York City, focused on training AI models capable of decoding thought processes in real time. Additionally, a new engineering hub in San Diego supports the company’s goal to build the world’s most advanced brain interfaces.
Synchron CEO and Founder Tom Oxley emphasized, “We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercializing the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
Expert Endorsements
Industry leaders recognize Synchron’s innovation as transformative. Campbell Murray, MD, Co-Founder and Managing Partner at Double Point Ventures, stated, “Synchron is building the first truly scalable, minimally invasive brain-computer interface that can be deployed in everyday healthcare. Its fusion of neurovascular access, breakthrough device engineering, and adaptive AI marks a fundamental step toward restoring digital agency to people with paralysis.”
Dr. Bob Langer, Executive Chairman of T.Rx Capital, added, “Synchron’s work is expanding the frontier of what’s possible between the human brain and technology. This next phase brings us closer to a future where brain interfaces can potentially unlock entirely new dimensions for healthcare.”
Next Steps
With the fresh capital injection, Synchron plans to accelerate pivotal clinical trials, prepare for the commercial launch of the Stentrode™ BCI system, and continue hiring neuroscientists, engineers, and operational staff to push the boundaries of next-generation brain-computer interface technology.
About Synchron
Synchron is at the forefront of developing minimally invasive brain-computer interfaces designed to restore communication, mobility, and independence for people living with paralysis. Their flagship Stentrode™ platform offers a groundbreaking endovascular approach that translates thought into digital actions without open-brain surgery, combining neurointerventional techniques, device engineering, and NeuroAI. Headquartered in New York City, Synchron also maintains a cutting-edge engineering and research hub in San Diego, California.
For more information, visit: www.synchron.com
Media Contact:
Kimberly Ha
Email: kha@synchron.com
Tags: #BCI #BrainComputerInterface #Communication #Funding #Neurotech
